NAD+: What the Evidence Actually Shows

Search "NAD+" and you will find a genuinely large scientific literature — hundreds of papers on a coenzyme that every living cell needs for energy metabolism and DNA repair. That volume is real, and it is also the reason NAD+ is one of the easiest compounds on this site to oversell: a large basic-science literature about an intracellular molecule is not the same thing as a human trial record for buying that molecule as an injection, a nasal spray, or an oral liquid — which is exactly what this site's NAD+ provider board tracks across 38 ranked sellers. This article keeps those two literatures separate throughout, because the gap between them is the actual finding.

What NAD+ actually is, and why supplementing it is plausible in theory

Nicotinamide adenine dinucleotide (NAD+) is a coenzyme present in every cell, central to redox reactions and serving as a required cofactor for two enzyme families implicated in aging biology: sirtuins (linked to gene-expression regulation and metabolic health) and PARPs (linked to DNA-damage repair)¹. Total-body NAD+ is reported to decline with age, and that decline is the entire rationale behind "NAD+ boosting" as a category — restore the coenzyme, restore the downstream cellular processes it supports. That is a coherent hypothesis and a real basic-science literature. It is also, on its own, a mechanism story, not a demonstrated outcome — the same category of claim this site's other evidence reviews have flagged when a proposed pathway gets treated as settled before anyone tests whether raising the level actually changes a health outcome in a person who takes the product.

What the human trial evidence for NAD+-boosting compounds actually shows — and which product it's actually about

The most useful single source located for this article is a 2026 PRISMA-guided systematic review that did the sorting work directly: 113 eligible studies (33 human, 80 rodent) published between January 2010 and October 2025, evaluating NAD-related compounds given either orally or parenterally². Its own synthesis draws a sharp line by route of administration. Oral NAD+ precursors — nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) — "consistently demonstrated biochemical target engagement" (measurable increases in circulating or cellular NAD-related metabolites) across 28 randomized human trials, "and were generally well tolerated over weeks to months." But on the outcomes that would actually matter to someone paying for the product — "functional, metabolic, vascular, and other healthspan-relevant outcomes" — the same review reports those effects "were heterogeneous and often null or endpoint-specific."

That is the more favorable half of the finding. The less favorable half is the one that matters most for this site's board specifically, and it is stated as plainly as evidence-reporting gets: "No eligible outcomes trials evaluated intravenous or intramuscular NAD⁺ itself for anti-aging or wellness indications²." Not "limited evidence." Not "mixed results." Zero eligible trials, for the injectable/IV form of NAD+ itself, in a review covering nearly sixteen years of literature through late 2025. The review did locate one nonrandomized intravenous NMN study (a precursor, not NAD+ itself, and non-randomized) that contributed short-term safety and biomarker data, and one intravenous NAD+ pharmacokinetic pilot — explicitly logged as "contextual evidence only," because it measured blood and urine chemistry, not a health outcome. A separate 2026 review reaches the identical conclusion independently: "Intravenous NAD⁺ administration is less well characterized and lacks robust clinical validation¹."

The one human study of directly infused NAD+ — and what it actually found

That "contextual evidence only" pharmacokinetic pilot is worth reading directly rather than taking on faith, because it is the entire published human evidence base for what happens when NAD+ itself — not a precursor — is put into a person's bloodstream. Researchers gave a 6-hour, continuous 3 μmol/min intravenous NAD+ infusion and tracked plasma and urine NAD+ and its metabolites throughout³. The result, read directly from the paper, is not the clean "NAD+ levels rose" story the marketing framing implies: "no change in plasma [NAD+] or metabolites... were observed until after 2 h." For the first two hours of a six-hour infusion, the study's own measurements found no detectable change. What did rise, later, was urinary excretion of NAD+ itself and one of its breakdown products (methylnicotinamide) — consistent with the infused NAD+ being rapidly metabolized and cleared by the body's own NAD+-degrading enzymes (NAD+ glycohydrolase and NAD+ pyrophosphatase) rather than simply accumulating. This is real, useful pharmacokinetic data. It is not evidence that IV NAD+ raises anything a reader would recognize as "my NAD+ levels" in a simple, sustained way, and it measures no clinical outcome at all — a fact the 2026 systematic review above states explicitly by excluding it from its own outcomes analysis.

What actually happens during an NAD+ IV infusion — the safety picture this site's readers should have before buying one

Separate from whether IV NAD+ works, there is a real, recently published, real-world safety finding worth stating plainly: a 2026 retrospective review of electronic medical records from a commercial IV-therapy chain compared clients who received four consecutive days of 500 mg NAD+ IV against clients who received NR IV instead⁴. Its own RESULTS text: "Participants that received NAD+ IV reported moderate to severe gastrointestinal symptoms, increased heart rate, and chest pressure during infusions," while the NR IV group experienced only "minor tongue, jaw, and arm tingling and mild cramping." Every symptom in both groups resolved once the infusion finished, and no significant changes were found on standard safety labs (ALT, AST, hsCRP, BUN/creatinine, TSH) — but the NAD+ IV group's own infusions took nearly three times as long on average (97 minutes versus 37 minutes for NR IV) specifically because clinicians had to slow the drip rate to manage those symptoms. One secondary metabolic finding is worth flagging rather than smoothing over: HDL-C (the "good" cholesterol marker) decreased significantly in the NAD+ IV group over the 30-day follow-up, while the NR IV group's own significant change was a decrease in HbA1c — a difference the study's authors describe as "variable" and in need of further investigation, not a settled benefit for either compound.

This is also the direct, sourced reason this article does not point readers to an NAD+ reconstitution calculator the way this site's other injectable-molecule reviews do. Every other calculator this site runs does one job — vial-to-syringe arithmetic — for a product genuinely sold as a lyophilized powder reconstituted with bacteriostatic water. NAD+, as this board's own 38 rows document, is sold across at least three different routes (injectable, nasal spray, oral liquid) with pricing overwhelmingly structured as a monthly subscription rather than a per-vial figure, and the real, published safety concern for the injectable form specifically is not a dosing-arithmetic question at all — it is an infusion-RATE question, the exact detail a vial/diluent/dose calculator has no way to represent responsibly. Building one here would either ignore that finding or imply a false reassurance a generic math tool cannot back up.

Where the strongest RCT in this whole literature actually points — and why it isn't about what's on this board

If a reader wants to know what the single best-designed randomized controlled trial in the entire NAD+ literature actually found, it exists — but it is not about the product this board ranks. A 2026 Phase 2, single-site, 2×2 factorial RCT tested nicotinamide riboside (an oral NAD+ precursor, 300-900 mg/day by weight) combined with an individualized exercise program in 66 patients with Friedreich's ataxia, a rare neurodegenerative disease⁶. The combination arm (nicotinamide riboside plus exercise) showed a statistically significant improvement in cardiopulmonary fitness (peak VO2) versus control (difference 0.21 L/min, 95% CI 0.05 to 0.36, p=0.0299) — a genuine, well-designed, positive RCT result. But read the arms separately, and nicotinamide riboside alone (no exercise) was NOT significantly different from control (difference 0.10, 95% CI -0.05 to 0.26, p=0.188). This is the honest shape of the best evidence NAD+-adjacent supplementation has: real, in a rare-disease population, for an oral precursor rather than injectable NAD+ itself, and even then only as an add-on to exercise rather than as a standalone effect.

The regulatory picture

A live DailyMed search for "NAD" (93 results, checked 2026-08-04) returns no FDA-approved NAD+ drug product of any kind — the results are Nadolol (an unrelated beta-blocker matched only because it contains the letters "NAD"), homeopathic combination remedies listing "Nadidum" among a dozen other ingredients, and over-the-counter cosmetic or patch listings⁷. That matches what this site's own NAD+ board found independently. Unlike BPC-157, TB-500, and GHK-Cu — each currently moving through FDA's Pharmacy Compounding Advisory Committee 503A bulk-substance nomination process, documented in this site's reviews of those three peptides — NAD+ is not part of that same fight. It is a naturally occurring coenzyme with an established chemical identity, not a novel synthetic peptide under nomination review, so its absence from PCAC's 2026 meeting agendas reflects a different regulatory category rather than an earlier, unresolved stage of the same review. Two registered clinical trials confirm interest in the injectable form's basic tolerability is current and ongoing rather than settled: NCT06919328 (recruiting) and NCT06382688 (status unknown), both sponsored by the same research group and both explicitly framed around comparing NAD+ IV's subjective tolerability against nicotinamide riboside IV — not testing whether either one works⁸⁹.

What this means if you're considering NAD+

Put together, the honest picture is this: NAD+'s basic cell biology is real and well established, and the case for "boosting" it is a coherent hypothesis rather than a fabricated one. But the actual human trial record splits sharply by product, and the split matters for anyone shopping this site's board specifically. Oral NAD+ precursors (NR, NMN) — not what most of this board's rows sell — have a real, if mixed, RCT literature: they reliably raise blood NAD+-related metabolites, and the best single result anywhere in that literature (the Friedreich's ataxia trial above) is a genuine positive finding, in a rare-disease population, as part of a combination with exercise. Injectable and IV NAD+ — the product most of this board's 38 rows actually sell — has zero located outcome trials, one pharmacokinetic pilot that didn't detect a plasma rise in its first two hours, and one real-world tolerability study documenting genuine infusion-related gastrointestinal and cardiovascular symptoms serious enough to require slowing the drip. Nasal spray and oral liquid NAD+, also sold across this board's roster, have no dedicated human trial of any kind located for either specific route.

None of that means NAD+ is a scam — the tolerability data above shows real clinics tracking real safety markers, and nothing in the literature located here suggests lasting harm. It means the specific claim implied by an NAD+ IV or injection product — that this exact route delivers the cellular-aging benefits the basic-science literature documents — has not been tested in a published human outcome trial, as of a review covering literature through late 2025. For a reader who still wants to compare where to buy it, our NAD+ provider comparison reads pharmacy sourcing, disclosed pricing, and product form (injectable, nasal spray, or oral liquid) directly off each of the 38 sellers' own sites, the same disclosure-first method every board on this site uses — including which rows publish no price at all rather than the subscription structure most others disclose. NAD+ is also this site's single most common "also sells" cross-compound, frequently bundled with Glutathione by the same sellers (Oak markets the two together as one checkout line); our Glutathione evidence review applies the identical route-by-route discipline to that board, and the honest evidence gap there follows a similar shape for a different reason.